MS and Demyelinating Disorders

Health care professionals who work in the field of neurology comment on their experience using interferon therapies and glatiramer acetate as treatment for relapsing multiple sclerosis.

The rationale for early treatment of multiple sclerosis, and an overview of limitations that impact the management of relapsing multiple sclerosis.

The Swedish treatment strategy—one of mostly induction—was associated with a 24% reduction in the rate of reaching EDSS score of 3 and a 25% reduction in the rate of reaching an EDSS score of 4.

Watch the "COVID-19 and MS Summit – Infections and Immunizations in the Era of COVID-19" broadcast today!

The clinical research director of the UCSF Multiple Sclerosis Center shared his perspective on the history of clinical care for neuromyelitis optica spectrum disorder in light of 3 recent FDA approvals.

Investigators found that frequency of MOG-Ab associated NMOSD was not significantly different between Asian and Caucasian populations despite the prevalence of NMOSD in Asian regions.

The rate of patients demonstrating impairment on cognitive assessments such as CVLTII, BVMT-R, and SDMT significantly decreased after treatment with fingolimod at 5-year follow-up.

A recent systematic review investigated the use of virtual reality as a therapeutic tool compared to conventional interventions, finding its use may improve quality of life, fatigue, and balance.

Lesions in the canalicular and intracranial optic nerve, area postrema, medulla, and cervical spinal cord were prominent in patients with aquaporin-4–NMOSD.

The innovative nonsurgical device has previously received market authorization to treat gait deficit due to mild-to-moderate symptoms from multiple sclerosis.

The full approval for BNT162b2 (Comirnaty; Pfizer/BioNTech) will afford physicians greater prescribing capability and is expected to play a role in driving workplace vaccine mandates.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending August 21, 2021.

The agent’s safety profile has been studied in more than 1200 individuals to date across several inflammatory diseases, with data indicating that the high selectivity of fenebrutinib may limit off-target effects.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 20, 2021.

Important insight related to individualized treatment approaches for patients with relapsing multiple sclerosis.

An overview of revisions to the McDonald criteria used to help diagnose relapsing multiple sclerosis, and recommendations to follow when referring to criteria and imaging results when evaluating patients.

The professor of neurology at the Mayo Clinic College of Medicine highlighted the importance of the diagnostic process and implementing an early treatment regimen for patients with NMOSD.

Investigators used statistical analysis to evaluate the effectiveness of the treatment method, with results indicating it could be a viable method for patients with MS.

Multivariable logistic regression models found age to be the only characteristic associated with the risk of CELs at baseline in all datasets, with a higher age associated with a lower risk of CELs.

Microvesicles excellently discriminated between the relapsing-remitting MS and control groups and between radiologically isolated syndrome and unspecific brain lesions.

The professor of neurology at Mayo Clinic College of Medicine discussed which biomarkers have shown the most relevancy in NMOSD and which deserve more attention.

Program chairs Fred D. Lublin, MD, and Stephen Silberstein, MD, offer insight into the third annual IFN meeting, which is set for September 17-18, 2021, to be held in a virtual setting.

Here's what is coming soon to NeurologyLive.

The professor of neurology at Mayo Clinic College of Medicine discussed several areas within the neuromyelitis optica spectrum disorder that are of interest for ongoing and new research efforts.

Patients with AQP4+NMOSD with long cord lesion showed higher annualized atrophy rate of normalized grey matter volume compared with those without long cord lesion.

Key opinion leaders in multiple sclerosis (MS) discuss the future of relapsing MS management and unmet needs.

Expert neurologists discuss current and future biomarkers relevant to relapsing multiple sclerosis including cerebrospinal fluid neurofilament.

The director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center spoke on what he is looking forward to at the 2021 International Congress on the Future of Neurology.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 13, 2021.